/ RZLT
Rezolute Shares Collapse 90% After Late-Stage Study Misses Primary Endpoint
Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in treating congenital hyperinsulinism.
December 11, 2025